Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Invested Capital (2022 - 2025)

Xeris Biopharma Holdings' Return on Invested Capital history spans 4 years, with the latest figure at 0.05% for Q2 2025.

  • For the quarter ending Q2 2025, Return on Invested Capital rose 13.0% year-over-year to 0.05%, compared with a TTM value of 0.05% through Jun 2025, up 13.0%, and an annual FY2024 reading of 0.17%, up 4.0% over the prior year.
  • Return on Invested Capital for Q2 2025 was 0.05% at Xeris Biopharma Holdings, up from 0.11% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.05% in Q2 2025, with the low at 0.61% in Q1 2022.
  • Average Return on Invested Capital over 4 years is 0.29%, with a median of 0.24% recorded in 2023.
  • Year-over-year, Return on Invested Capital surged 32bps in 2023 and then grew 3bps in 2024.
  • Tracing XERS's Return on Invested Capital over 4 years: stood at 0.38% in 2022, then skyrocketed by 40bps to 0.23% in 2023, then rose by 27bps to 0.17% in 2024, then skyrocketed by 73bps to 0.05% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Return on Invested Capital are 0.05% (Q2 2025), 0.11% (Q1 2025), and 0.17% (Q4 2024).